Chapter 11
Structuring the Deal
Payment and Legal Considerations
If you can't convince them, confuse them.
—Harry S. Truman
Inside M&A: pfizer acquires wyeth labs despite tight credit markets
Pfizer and Wyeth began joint operations on October 22, 2009, when Wyeth shares stopped trading and each Wyeth share was converted to $33 in cash and 0.985 of a Pfizer share. Valued at $68 billion, the cash and stock deal was first announced in late January of 2009. The purchase price represented a 12.6% premium over Wyeth's closing share price the day before the announcement and a 29% premium over the same day the prior month. Investors from both firms celebrated as Wyeth's shares rose 12.6% and Pfizer's 1.4% on the news. The announcement seemed to offer ...
Get Mergers, Acquisitions, and Other Restructuring Activities, 6th Edition now with the O’Reilly learning platform.
O’Reilly members experience books, live events, courses curated by job role, and more from O’Reilly and nearly 200 top publishers.
